Position in ENLV
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$584,328
-$911,796 QoQ
Shares Held
628,310
+89.8% QoQ
Ownership
3.73%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2021
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ENLV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026ARK Investment Management LLC holds $1,308,181,852 across 17 Biotechnology names. ENLV ranks #17 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CRSP |
CRISPR Therapeutics AG
|
11,313,623 | $538,189,046 | |
| 2 | BEAM |
Beam Therapeutics Inc.
|
12,133,433 | $289,139,708 | |
| 3 | NTLA |
Intellia Therapeutics, Inc.
|
14,509,247 | $186,008,546 | |
| 4 | RXRX |
Recursion Pharmaceuticals, Inc.
|
40,212,769 | $123,453,200 | |
| 5 | ABSI |
Absci Corp
|
13,726,169 | $41,178,507 | |
| 6 | NRIX |
Nurix Therapeutics, Inc.
|
1,721,135 | $26,677,592 | |
| 7 | PRME |
Prime Medicine, Inc.
|
6,246,827 | $21,738,957 | |
| 8 | IONS |
Ionis Pharmaceuticals Inc
|
288,716 | $21,679,684 |
All Filings in ENLV
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $584,328 | 628,310 | Shares | Sole | 2026-05-12 | |
| 2022-06-30 | $1,496,124 | 331,001 | Shares | Sole | 2022-07-11 | |
| 2022-03-31 | $2,427,977 | 434,343 | Shares | Sole | 2022-04-19 | |
| 2021-12-31 | $2,183,175 | 349,308 | Shares | Sole | 2022-01-28 | |
| 2021-09-30 | $4,523,034 | 457,797 | Shares | Sole | 2021-11-12 | |
| 2021-06-30 | $4,581,782 | 514,807 | Shares | Sole | 2021-08-05 | |
| 2021-03-31 | $5,283,431 | 476,414 | Shares | Sole | 2021-05-13 | |
| No filing history on record for this holder in this stock. | ||||||